Скачать или смотреть Phase 3, open-label, randomized trial comparing belamaf to Pd in RRMM: DREAMM-3 study

Dr. Katja Weisel presented a study evaluating the efficacy and safety of single-agent belantamab mafodotin (belamaf) (a first-in-class antibody drug conjugate) compared to pomalidomide plus low-dose dexamethasone (Pd) in patients with relapsed and refractory multiple myeloma. The trial, known as the DREAMM-3 trial, included 325 patients and assessed progression-free survival as the primary endpoint. Although belamaf demonstrated a longer median progression-free survival compared to pomalidomide, the difference did not reach statistical significance. However, belamaf showed a deeper and more durable response rate, with a higher rate of stringent complete responses. The adverse events were manageable, with ocular toxicity being the most notable side effect, which was reversible in most cases. Patient-reported outcomes indicated that belamaf was well tolerated and had a positive impact on important health outcomes.

The DREAMM-3 trial compared single-agent belamaf to pomalidomide plus low-dose dexamethasone in patients with relapsed and refractory multiple myeloma.
The trial included 325 patients and evaluated progression-free survival as the primary endpoint.
Belamaf, a first-in-class antibody drug conjugate, targets BCMA and induces cell death through various mechanisms.
The median age of the patients was 68, and about 20% of patients were triple refractory.
The median progression-free survival was longer for belamaf (11.2 months) compared to pomalidomide (7.0 months), although the difference was not statistically significant.
The response rate was higher for belamaf compared to pomalidomide, with a more durable and deeper response observed.
The adverse events were manageable, with neutropenia being more pronounced in the pomalidomide group.
Ocular toxicity was a notable side effect of belamaf, but it was mostly reversible.
Patient-reported outcomes indicated that belamaf was well tolerated and had a positive impact on important health outcomes.

Authors:
Katja Weisel, Vania TM Hungria, Atanas Radinoff, Sosana Delimpasi, Gabor Mikala, Tamas Masszi, Jian Li, Marcelo Capra, Morio Matsumoto, Neal Sule, Mary Li, Astrid McKeown, Wei He, Shelley Bright, Brooke Currie, Julia Boyle, Joanna Opalinska, Meletios A. Dimopoulos


_______________
Improving Lives | Finding the Cure

Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy.

Subscribe to our channel:    / imfmyeloma  

Visit our website at: https://www.myeloma.org

Find us online:
Facebook: @myeloma |   / myeloma  
Twitter: @IMFMyeloma |   / imfmyeloma  
Instagram: @imfmyeloma |   / imfmyeloma  
LinkedIn:   / international-myeloma-foundation  

Support the IMF | Donate Now! https://secure.myeloma.org/page/40697...
Category
Nonprofits & Activism
License
Standard YouTube License

In most cases, captions are autogenerated by YouTube.